The forecast for the cardiovascular system medicine sales in Canada from 2024 to 2028 indicates a gradual decline per capita. The sales value in 2024 stands at 60 US Dollars per capita, decreasing to 57 US Dollars per capita by 2028. Comparing year-on-year variations, we observe a decline of approximately 1.7% annually. Viewing the trend from 2023, the compounded average growth rate (CAGR) over the five-year period reflects this decreasing trajectory, averaging a reduction of 1.3% per year.
Future trends to watch for include advancements in treatment technologies, potential healthcare reforms, and demographic shifts such as the aging population. These factors could either mitigate or exacerbate the projected decline.
